Evaluating emerging issues in epidemiology

Regulatory Toxicology and Pharmacology

Volumn 48, Issue 3, 2007, Pages 296-307

  Collins, James J ^a   Bukowski, John A ^b   Weed, Douglas L ^c   Brent, Robert L ^d   Klein, Patti ^e   Boerstoel Streefland, Mariette ^f   Sprafka, J Michael ^g   Williams, Amy Lavin ^h   Holsapple, Michael P ⁱ  

^a DOW CHEMICAL COMPANY   (United States)

^b WordsWorld Consulting   (United States)

^c The Weinberg Group   (United States)

^d Jefferson University   (United States)

^e DOW CORNING CORPORATION   (United States)

^f FOREST RESEARCH INSTITUTE   (United States)

^g PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^h NOBLIS   (United States)

ⁱ ILSI HEALTH AND ENVIRONMENTAL SCIENCES INSTITUTE   (United States)

Author keywords

Causality; Epidemiology; Evidence; Policy; Risk assessment; Risk communication

Indexed keywords

FENFLURAMINE; GESTAGEN; PHENTERMINE; SILICONE;

ARTICLE; AUTOIMMUNE DISEASE; BIRTH DEFECT; BREAST ENDOPROSTHESIS; CANCER RISK; COMMUNITY ASSESSMENT; CONGENITAL MALFORMATION; EPIDEMIOLOGY; EVALUATION; EVIDENCE BASED MEDICINE; GOVERNMENT; HEALTH PROGRAM; HUMAN; INDUSTRY; PRIORITY JOURNAL; PUBLIC HEALTH; TAMPON; TOXIC SHOCK SYNDROME; VALVULAR HEART DISEASE; WASTE GAS MANAGEMENT;

CAUSALITY; COOPERATIVE BEHAVIOR; EPIDEMIOLOGIC METHODS; EPIDEMIOLOGY; HISTORY, 20TH CENTURY; HUMANS; INFORMATION DISSEMINATION; PUBLIC HEALTH; RISK ASSESSMENT; RISK MANAGEMENT; UNITED STATES;

EID: 34447512884     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2007.04.002     Document Type: Article

References (138)

1. Ambani L.M., Joshi N.J., et al. Are hormonal contraceptives teratogenic?. Fertil Steril 28 (1977) 791-797
2. American Medical Women's, Association, 1998. Silicone gel breast implants. J. Am. Med. Assoc. 53, 33-34, 47.
3. American Society of Plastic and Reconstructive Surgeons and American Society for Aesthetic Plastic Surgery, 1998. Joint postion statement: silicone breast implants: Scientific update www.plasticsurgery.org.
4. Aro T., Haapakoski H., et al. Multivariate analysis of the risk indicators of limb reduction defects. Int. J. Epidemiol. 13 (1984) 459-464
5. ATSDR, 2001. Summary of Findings: Historical Reconstruction of the Water-distribution Serving the Dover Township Area, New Jersey: January 1962-December 1996, ATSDR, Atlanta, GA.
6. Australian Commonwealth Department of Health and Family Services, T.G.A., 1998. Breast Implant Information Booklet (second ed.).
7. Baldwin C.M., and Kaplan E.N. Silicone-induced human adjuvant disease?. Ann. Plast. Surg. 10 (1983) 270-273
8. Benagiano G., and Fraser I. The depo-provera debate commentary on the article Depo-Provera, a critical analysis. Contraception 24 (1981) 493-528
9. Berkel H., Birdsell D.C., et al. Breast augmentation: a risk factor for breast cancer?. N. Engl. J. Med 326 25 (1992) 1649-1653
10. Birdsell D.C., Jenkins H., et al. Breast cancer diagnosis and survival in women with and without breast implants. Plast. Reconstr. Surg. 92 5 (1993) 795-800
11. Bondurant S., Ernster V., et al. Safety of Silicone Breast Implants (Report of the Committee on the Safety of Silicone Breast Implants, Division of Health Promotion and Disease Prevention, Institute of Medicine) (1999), National Academy Press, Washington, DC
12. Bracken M.B. Oral contraception and congenital malformations in offspring: A review and meta analysis of the prospective studies. Obstet. Gynecol. 76 (1990) 552-557
13. Bracken M.B., Holford T.R., et al. Role of oral contraception in congenital malformations of offspring. Int. J. Epidemiol. 7 4 (1978) 309-317
14. Brent R.L. Kudos to the food and drug administration: reversal of the package warning for birth defects for oral contraceptives. Teratology 39 (1989) 93-94
15. Brent R.L. Non-genital malformation following exposure to progestional drugs: the final chapter of an erroneous allegation. Birth Defects Part A 73 (2005) 906-918
16. Briggs M.H., Briggs M., et al. Sex Hormone Exposure During Pregnancy and Malformations (1979), Academic Press, New York 51-89
17. Brinton L.A., Lubin J.H., et al. Breast cancer following augmentation mammoplasty (United States). Cancer Causes Control 11 (2000) 819-827
18. Caldwell G.G., and Heath C.W. Case clustering in cancer. South Med. J. 69 12 (1976) 1598-1602
19. Carbone J.B., Figurska K., et al. Effect of gestational sex steroid exposure on limb development and endochondral ossification in the pregnant C57B1/6J mouse: medroxyprogesterone acetate. Teratology 42 (1990) 121-130
20. Carbone J.P., Baldridge R.C., et al. Characterization of cytosolic glucocorticoid receptor of fetal rat epiphyseal chondrocytes. J. Steroid Biochem. 35 (1990) 495-505
21. Carbone J.P., and Brent R.L. Genital and nongenital teratogenesis of prenatal progestagen therapy. The effects of 17 a-hydroxyprogeste-rone caproate on embryonic and fetal development and endochondral ossification in the C57B1/6J mouse. Am. J. Obstet. Gynecol. 169 (1993) 1292-1298
22. CDC, 1980a. Follow-up on toxic shock syndrome-United States. Mor. Mortal Wkly. Rep. 29, 297-299.
23. CDC, 1980b. Toxic shock syndrome-United States. Mor. Mortal Wkly. Rep. 29, 229-230.
24. CDC, 1980c. Toxic shock syndrome-Utah. Mor Mortal Wkly. Rep. 29, 495-496.
25. CDC, 1981. Toxic shock syndrome-United States 1970-1980. Mor. Mortal Wkly. Rep. 30, 25-28.
26. CDC, 1990. Guidelines for investigating clusters of health events. Mor. Mortal Wkly. Rep. 39(RR-11), 1-16.
27. Check J.H., Rankin A., et al. The risk of fetal anomalies as a result of progesterone therapy during pregnancy. Fertil. Steril. 45 (1986) 575-577
28. Check J.H., Wu C.H., et al. Decreased abortions in HMG-induced pregnancies with prophylactic progesterone therapy. Int. J. Fertil. 30 (1958) 45-47
29. Chez R.A. Proceedings of the symposium progesterone, progestins, and fetal development. Fertil. Steril. (1970) 16-26
30. Connell E.B. The exploitation of autoimmune disease: breast implant litigation and its dire implications for women's health. J. Women's Health. 7 (1998) 329-338
31. Conolly H.M., and Et A. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 337 (1997) 581-588
32. Corfman P.A. Labeling guidance for combination oral contraceptives. Contraception 37 (1988) 433-455
33. Covello V.T. Risk communication and occupational medicine. J. Occup. Med. 35 (1993) 18-19
34. Czeizel A., Erodi E., et al. An epidemiological study on undescended testis. J. Urol. 126 4 (1981) 524-527
35. Czeizel A.E., and Kodaj I. A changing pattern in the association of oral contraceptives and the different groups of congenital limb deficiencies. Contraception 51 (1995) 19-24
36. Darling M.R., and Hawkins D.F. Sex hormones in pregnancy. Clin. Obstet. Gynecol. 8 (1981) 405-419
37. Deapen D.M., and Brody G.S. Augmentation mammaplasty and breast cancer: a 5-year update of the Los Angeles study. Plast. Reconstr. Surg. 89 (1992) 660-665
38. Deapen D.M., Pike M.C., et al. The relationship between breast cancer and augmentation mammaplasty: an epidemiologic study. Plast. Reconstr. Surg. 77 3 (1986) 361-367
39. Diamond, B.A., Hulka, B.S., et al., 1998. Rule 706 National Science Panel Report, United States District Court, Northern District of Alabama. Southern Division. In re: Silicone Gel Breast Implant Products Liability Litigation (MDL 926).
40. Donawa N.E., Schmid G.R., et al. Toxic shock syndrome: chronology of state and federal epidemiologic studies and regulatory decision making. Public Health Rep. 99 (1984) 342-349
41. Etheridge E.W. Sentinel for Health: A History of the Centers for Disease Control (1992), Springer, Berlin
42. European Committee on Quality Assurance and Medical Devices in Plastic, S., 1998. Consensus Declaration on Breast Implants.
43. FDA (1999). Progestational Drug Products for Human Use; Requirements for Labeling Directed to the Patient.
44. Ferencz C., Matanoski G.M., et al. Maternal hormone therapy and congenital heart disease. Teratology 21 (1980) 225-239
45. Ferguson J.H. Silicone breast implants and neurologic disorders. Report of the Practice Committee of the American Academy of Neurology. Neurology 48 (1997) 1504-1507
46. Food and Drug Administration (2004). FDA provides pathway for sponsors seeking approval of breast implants. FDA News.
47. Foss, K., 2006. Food and Drug Administration PMA approval letter. Re: P030053. Mentor MemoryGel Silicone Gel-Filled Breast Implants, November 17, 2006.
48. Foster K.R., Vecchia P., et al. Science and the precautionary principle. Science 288 (2000) 979-981
49. Friis S., McLaughlin J.K., et al. Breast implants and cancer risk in Denmark. Int. J. Cancer 71 (1997) 956-958
50. Friis S., Mellemkjaer L., et al. Connective tissue disease and other rheumatic conditions following breast implants in Denmark. Ann. Plast. Surg. 39 (1997) 1-8
51. Gal I., Kirman B., et al. Hormonal pregnancy tests and congenital malformations. Nature 216 (1967) 83
52. Glasser J.W., and Lee N.C. Does breast augmentation increase the risk of breast cancer?. Epidem. Intel. Serv 89 (1989) 43
53. Goujard J., and Rumeau-Rouquette C. First-trimester exposure to progestogen/oestrogen and congenital malformations. Lancet 1 (1977) 482
54. Gray R.H., and Pardthaisong T. In utero exposure to steroid contraceptives and survival during infancy. Am. J. Epidemiol. 134 (1991) 811
55. Greenberg G., Inman W.H.W., et al. Hormonal pregnancy tests and congenital malformations. Br. J. Med. 2 (1975) 191
56. Harvey M., et al. Toxic shock and tampons: evaluation of the epidemiologic evidence. J. Am. Med. Assoc. 248 (1982) 840-846
57. Health Canada (1998). It's Your Health.
58. Heinonen O.P., Sloane D., et al. Cardiovascular birth defects and antenatal exposure to female sex hormones. N. Engl. J. Med. 296 (1977) 67
59. Hensrud D.D., Connolly H.M., et al. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine. Mayo Clin. Proc. 74 (1999) 1191-1197
60. Hill A.B. The environment and disease: association or causation?. Proc. Roy. Soc. Med. 58 (1965) 295-300
61. Hochner-Celnikier D., Marandici A., et al. Estrogen and progesterone receptors in organs of prenatal cynmologous monkeys and the laboratory mouse. Biol. Reprod. 35 (1986) 633-640
62. Holmich L.R., Mellemkjaer L., et al. Stage of breast cancer at diagnosis among women with cosmetic breast implants. Br. J. Cancer 88 (2003) 832-838
63. Hulka B.S. Tampons and toxic shock syndrome (editorial). J. Am. Med. Assoc. 248 (1982) 872-874
64. Janerich D.T. Supportive hormone therapy and birth defects. Teratology 20 (1979) 483
65. Janerich D.T., Dugan J.M., et al. Congenital heart disease and prenatal exposure to exogenous sex hormones. Br. J. Med. 1 (1977) 1058
66. Janerich D.T., Piper J.M., et al. Oral contraceptives and birth defects. Am. J. Epidemiol. 112 (1980) 73
67. Janerich D.T., Piper J.M., et al. Oral contraceptives and congenital limb-reduction defects. N. Engl. J. Med. 291 14 (1974) 697-700
68. Kaiser W., Biesenbach G., et al. Human adjuvant disease: remission of silicone induced autoimmune disease after explanation of breast augmentation. Ann. Rheum. Dis. 49 (1990) 937-938
69. Kallen B., Rahmani T.M., et al. Infants with congenital limb reduction registered in the Swedish register of congenital malformations. Teratology 29 (1984) 73-85
70. Katz Z., Lancet M., et al. Teratogenicity of progestogens given during the first trimester of pregnancy. Obstet. Gynecol. 65 6 (1985) 775-780
71. Keith L., and Berger G.S. The relationship between congenital defects and the use of exogenous progestational contraceptive hormones during pregnancy: A 20-year review. Int. J. Gynaecol. Obstet. 15 (1977) 115-124
72. Kossovsky N., Zeidler M., et al. Surface dependent antigens identified by high binding avidity of serum antibodies in a subpopulation of patients with breast prostheses. J. Appl. Biomater. 4 (1993) 281-288
73. Lammer E.J., Cordero J.F., et al. Exogenous sex hormone exposure and the risk for VACTERL association. Teratology 34 (1986) 165-169
74. Lancet. Are sex steroids teratogenic?. Lancet 1 (1974) 1489-1490
75. Laurence K.M. Reply to Gal. Nature 240 (1972) 242
76. Levy E.P., Cohen A., et al. Hormone treatment during pregnancy and congenital heart disease. Lancet 1 (1973) 611
77. Loke K.Y., Sheena D., et al. Appetite suppressants and valvular heart disease a systematic review. BMC Clin. Pharmacol. 2 (2002) 6
78. Maslia M.L., Reyes J.J., et al. Public health partnerships addressing childhood cancer investigations: case study of Toms River, Dover Township, New Jersey, USA. Int. J. Hyg. Environ. Health 208 (2005) 45-54
79. Matsunaga E., and Shiota K. Threatened abortion, hormone therapy and malformed embryos. Teratology 20 (1979) 469-480
80. Michaelis J., Michaelis H., et al. Prospective study of suspected associations between certain drugs administered during early pregnancy and congenital malformations. Teratology 27 (1983) 57-64
81. Mulvihill J.J., Mulvihill C.G., et al. Prenatal sex hormone exposure and cardiac defects in man. Teratology 9 (1974) A30
82. Neutra R.R., and Delpizzo V. Transparent democratic foresight strategies in the California EMF Program. Public Health Rep. 117 6 (2002) 553-563
83. NJDHSS, 1997. Childhood cancer incidence health consultation: a review and analysis of cancer registry data, 1979-1995 for Dover Township (Ocean County), New Jersey: NJDHSS.
84. NJDHSS and ATSDR, 2001a. Case-control study of childhood cancers in Dover Township (Ocean County), New Jersey: vol. I: Summary of the final technical report. Draft for Public Comment.
85. NJDHSS and ATSDR, 2001b. Public Health Assessment: Reich Farm CERCLIS Number NJD980529713, Dover Township, Ocean County, New Jersey.
86. NJDHSS, ATSDR, et al., 2003. Public Health Consultation: Drinking water quality analysis, March 1996-June 1999 United Water Toms River, Dover Township, Ocean County, New Jersey: NJDHSS.
87. Nocke W. Sind weibliche sexualsteroide teratogen? Ruckblick-Zwischenbilanz-Konsequenzen. Gynakologe 11 (1978) 119-141
88. Nora A.H., and Nora J.J. A syndrome of multiple congenital anomalies associated with teratogenic exposure. Arch. Environ. Health 30 (1975) 17
89. Nora J.J., and Nora A.H. Birth defects and oral contraceptives. Lancet 1 (1973) 941-942
90. Oakley G.A., Muir T., et al. Increased incidence of congenital malformations in children with transient thyroid-stimulating hormone elevation on neonatal screening. J. Pediatr. 132 (1998) 726-730
91. Oakley G.P. Threatened abortion, hormone therapy and malformed embryos. Teratology 20 (1979) 481-482
92. Oakley G.P., Flynt J.W., et al. Hormonal pregnancy tests and congenital malformations. Lancet 2 (1973) 256-257
93. Pardthaisong T., and Gray R.H. In utero exposure to steroid contraceptives and outcome of pregnancy. Am. J. Epidemiol. 134 (1991) 795-803
94. Pardthaisong T., Gray R.H., et al. Steroid contraceptive use and pregnancy outcome. Teratology 38 (1988) 51-58
95. Pardthaisong T., Yenchit C., et al. The long-term growth and development of children exposed to depo-provera during pregnancy or lactation. Contraception 45 (1992) 313-324
96. Peterson W.F. Pregnancy following oral contraceptive therapy. Obstet. Gynecol. 34 (1969) 363
97. Press R.I., Peebles C.L., et al. Antinuclear antibodies in women with silicone breast implants. Lancet 340 (1992) 1304-1307
98. Raman Wilms L., Lin in Tseng A., et al. Fetal genital effects of first-trimester sex hormone exposure: a meta-analysis. Obstet. Gynecol. 85 (1995) 141-149
99. Resseguie L.J., Hick J.F., et al. Congenital malformations among offspring exposed in utero to progestins, Olmsted County, Minnesota, 1936-1974. Fertil. Steril. 43 4 (1985) 514-519
100. Richardson S.D., Collette T.W., et al. Identification of drinking water contamination in the course of a childhood cancer investigation in Tom's River, New Jersey. J. Expo. Anal. Environ. Epidemiol. 9 (1999) 200-216
101. Rock J.A., Wentz A.C., et al. Fetal malformations following progesterone therapy during pregnancy: a preliminary report. Fertil. Steril. 44 1 (1985) 17-19
102. Rosenfield A. Oral and intrauterine contraception: a 1978 risk assessment. Am. J. Obstet. Gynecol. 132 (1978) 92
103. Rosenfield A., Maine D., et al. The Food and Drug Administration and medroxyprogesterone acetate. J. Am. Med. Assoc. 249 21 (1983) 2922-2928
104. Rotbart B., and Prestbo T. Taking rely off market cost Procter and Gamble a week of agonizing. Wall Street J. 1 (1980) 21
105. Rothman K.J. Clustering of disease. Am. J. Public Health 77 (1987) 13-15
106. Rothman K.J., Fyler D.C., et al. Exogenous hormones and other drug exposures of children with congenital heart disease. Am. J. Epidemiol. 109 4 (1979) 433-450
107. Rothman, K.J., Greenland, S. et al., 1998. Causation and Causal Inference, Philadelphia, PA, Lippincott-Raven, Second Edition 7-28.
108. Rothman K.L., and Louik C. Oral contraceptives and birth defects. N. Engl. J. Med. 299 (1978) 522
109. Savolainen E., Saksela E., et al. Teratogenic hazards of oral contraceptives analyzed in a national malformation register. Am. J. Obstet. Gynecol. 140 (1981) 521-524
110. Schardein J.L. Congenital abnormalities and hormones during pregnancy: a clinical review. Teratology 22 (1980) 251-270
111. Schlech W.F. Risk factors for development of toxic shock syndrome: association with a tampon brand. J. Am. Med. Assoc. 248 (1982) 835-839
112. Schulte P.A., Ehrenberg R.L., et al. Investigation of occupational cancer clusters: theory and practice. Am. J. Public Health 77 1 (1987) 52-56
113. Scialli A.R. Developmental effects of progesterone and its derivatives. Reprod. Toxicol. 2 (1988) 3-11
114. Seghatol F.F., and Rigolin V.H. Appetite suppressants and valvular heart disease. Curr. Opin. Cardiol. 17 (2002) 486-492
115. Shands K.N., et al. Toxic shock syndrome in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 cases. N. Engl. J. Med. 303 (1980) 1436-1442
116. Silicone Gel Breast Implants Independent Review, G. (1998). Silicone Gel Breast Implants: The Report of the Independent Review Group. Cambridge, The Report of the Independent Review Group, Jill Rogers Associates.
117. Smith E.S.O., Dafoe C.S., et al. An epidemiological study of congenital reduction deformities of the limbs. Br. J. Prev. Soc. Med. 31 (1977) 39-41
118. Smithells R.W. Oral contraceptives and birth defects. Med. Child Neurol. 23 (1981) 369-383
119. Spira N., Goujard J., et al. Etude teratogene des hormones sexuelles. Premiers resultats d'une enquete epidemiologique portant sur 20,000 femmes. Rev. Med. Fr. 41 (1972) 2683
120. Stakeman G., et al. Drug use during pregnancy and breast feeding. Acta Obstet. et. Gynecol. Scand. Suppl. 126 (1984) 1-54
121. Teuber S.S., Rowley M.J., et al. Anticollagen autoantibodies are found in women with silicone breast implants. J. Autoimmun. 6 (1993) 367-377
122. Todd J., et al. Toxic shock syndrome associated with phage group-I staphylococci. Lancet 2 (1978) 1116-1118
123. Torfs C.P., Milkovich L., et al. The relationship between hormonal pregnancy tests and congenital anomalies: a prospective study. Am. J. Epidemiol. 113 5 (1981) 563-574
124. Travis W.D., Balogh K., et al. Silicone granulomas: report of three cases and review of the literature. Hum. Pathol. 16 (1985) 19-27
125. Uretsky B.F., O'Brien J.J., et al. Augmentation mammaplasty associated with a severe systemic illness. Ann. Plast. Surg. 3 (1979) 445-447
126. Van Nunen S.A., Basten A., et al. Post-mammoplasty connective tissue disease. Arthritis Rheum. 25 (1982) 694-697
127. Vessey M.P. Contraceptive methods; risks and benefits. Br. Med. J. 2 (1978) 721
128. ® Silicone-Filled Breast Implants, November 17, 2006.
129. Warner E., Lipa M., et al. Silicone mastopathy mimicking malignant disease of the breast in Southeast Asian patients. CMAJ 144 (1991) 569-571
130. Weed D.L. Interpreting epidemiological evidence: how meta-analysis and causal inference methods are related. Int. J. Epidemiol. 29 (2000) 387-390
131. Weed D.L. Precaution, prevention and public health ethics. J. Med. Philios. 29 (2004) 313-332
132. Weisman M.H., Vecchione T.R., et al. Connective-tissue disease following breast augmentation: a preliminary test of the human adjuvant disease hypothesis. Plast. Reconstr. Surg. 82 4 (1988) 626-630
133. Wilson J.G., and Brent R.L. Are female sex hormones teratogenic?. Am. J. Obstet. Gynecol. 141 (1981) 567-580
134. Wiseman R.A., and Dodds-Smith I.C. Cardiovascular birth defects and antenatal exposure to female sex hormones: a reevaluation of some base data. Teratology 30 (1984) 359-370
135. World Health Organization Scientific, G., 1981. The effects of female sex hormones on fetal development and infant health: 1-76.
136. Yasuda M., and Miller J.R. Prenatal exposure to oral contraceptives and transposition of the great vessels in man. Teratology 12 (1975) 239-243
137. Young S. FDA rejects silicone breast implant request. CNN Health (2004)
138. Yovich J.L., Wilcox D.L., et al. Medroxyprogesterone acetate does not perturb the profile of steroid metabolites in urine during pregnancy. J. Endocrinol. 104 (1985) 453-459